EBIT: Income before interest and taxes.
Monte Rosa Therapeutics, Inc. (GLUE) had EBIT of $44.04M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$84.93M |
|
$46.88M |
|
-- |
|
$84.93M |
|
$40.89M |
|
$44.04M |
|
$3.67M |
|
$47.71M |
|
$47.65M |
|
$46.88M |
|
$46.88M |
|
$46.88M |
|
$46.83M |
|
|
EBIT |
$44.04M |
$46.08M |
|
82.15M |
|
82.96M |
|
$0.57 |
|
$0.57 |
|
| Balance Sheet Financials | |
$332.28M |
|
$29.34M |
|
$60.92M |
|
$393.20M |
|
$59.22M |
|
-- |
|
$58.82M |
|
$118.04M |
|
$275.16M |
|
$275.16M |
|
$275.16M |
|
61.51M |
|
| Cash Flow Statement Financials | |
$-45.49M |
|
$-100.23M |
|
$0.01M |
|
$229.12M |
|
$83.41M |
|
$-145.71M |
|
$5.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.61 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
51.85% |
|
51.85% |
|
-- |
|
56.17% |
|
55.20% |
|
$-47.08M |
|
-- |
|
-- |
|
-- |
|
0.22 |
|
-- |
|
60.32 |
|
1.49 |
|
17.04% |
|
17.04% |
|
11.92% |
|
17.04% |
|
$4.47 |
|
$-0.57 |
|
$-0.55 |
|